Company / Cash & Equivalents
Glucotrack, Inc. Cash & Equivalents History
FY2014-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.8M
FY2020
5-year range
$97.1K / $9.8M
FY2016-FY2020
Trend
+2246.5%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +2247% YoY in FY2020, a notable deviation from the 6-year average annual change of +488%.
Based on SEC 10-K filings.
$10M in FY2020 with a 5-year CAGR of +32.7%.
Improved from $97,079 to $10M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +304.1%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2020, cash & equivalents increased 2246.5% year-over-year.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $9.8M | +2246.5% |
| FY2019 | $418.6K | +331.2% |
| FY2018 | $97.1K | -34.8% |
| FY2017 | $148.8K | -97.4% |
| FY2016 | $5.8M | +144.2% |
| FY2015 | $2.4M | +339.1% |
| FY2014 | $543.4K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026